Torcetrapib

Torcetrapib Basic information
Product Name:Torcetrapib
Synonyms:CP 529414;(2R)-ethyl 4-((3,5-bis(trifluoroMethyl)benzyl)(Methoxycarbonyl)aMino)-2-ethyl-6-(trifluoroMethyl)-3,4-dihydroquinoline-1(2H)-carboxylate;Torcetrapib (CP-529414);cp529;(2R,4S)-ethyl 2-ethyl-4-(methoxycarbonyl)-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate;Torcetropib;CS-156;TORCETRAPIB-D3
CAS:262352-17-0
MF:C26H25F9N2O4
MW:600.47
EINECS:
Product Categories:Inhibitor;Aromatics;Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals
Mol File:262352-17-0.mol
Torcetrapib Structure
Torcetrapib Chemical Properties
Melting point 54-58°C
Boiling point 504.8±50.0 °C(Predicted)
density 1.42
storage temp. Store at RT
solubility DMSO: >5mg/mL
form powder
pka-1.87±0.40(Predicted)
color white
optical activity[α]/D >-70°
CAS DataBase Reference262352-17-0(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
MSDS Information
Torcetrapib Usage And Synthesis
Chemical PropertiesOff-White Low Melting Solid
UsesCholesteryl ester transfer protein (CETP) inhibitor. Antilipemic; antiatherosclerotic.
DefinitionChEBI: Torcetrapib is a member of quinolines, a carbamate ester and a member of (trifluoromethyl)benzenes. It has a role as an anticholesteremic drug and a CETP inhibitor.
Biological Activitytorcetrapib is a cetp inhibitor with ic50 of 37 nm, elevates hdl-c and reduces nonhdl-c in plasma. inhibition of cholesteryl ester transfer protein (cetp) has been shown to have a substantial effect on plasma lipoprotein levels.
in vitrotorcetrapib dose-dependently increases aldosterone release from h295r cells after either 24 or 48 h of treatment, this effect is mediated by calcium channel as calcium channel blockers completely blocks torcetrapib-induced corticoid release and calcium increase. torcetrapib (1 μm) significantly increases the expression of steroidogenic gene, cyp11b2 and cyp11b1, in h295r cell lines [1].
in vivoresearchers tested torcetrapib in rabbits fed an atherogenic diet at a dose sufficient to increase hdl-c by at least 3-fold. cetp activity was inhibited by 70–80% throughout the study. non-hdl-c increased in both groups, but there was no difference apparent by the study’s end [2].
storageRoom temperature
references[1] hu x, dietz jd, xia c, knight dr, loging wt, smith ah, yuan h, perry da, keiser j. torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. endocrinology. 2009;150(5):2211-9.
[2] morehouse la, sugarman ed, bourassa pa, sand tm, zimetti f, gao f, rothblat gh, milici aj. inhibition of cetp activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in new zealand white rabbits. j lipid res. 2007;48(6):1263-72.
[3] barter pj, caulfield m, eriksson m, grundy sm, kastelein jj, komajda m, lopez-sendon j, mosca l, tardif jc, waters dd, shear cl, revkin jh, buhr ka, fisher mr, tall ar, brewer b; illuminate investigators. effects of torcetrapib in patients at high risk for coronary events. n engl j med. 2007;357(21):2109-22.
Torcetrapib Preparation Products And Raw materials
p-(2-Methoxyethyl) phenol Benzyltriethylammonium chloride Ethanol Ethyl formate Torcetrapib Ethylbenzene Methoxydiethylborane Anisole Ethylparaben (Trifluoromethoxy)benzene CHLOROETHANE Ethyl cellulose p-Anisidine Diethyl ether Ethyl acetate p-Anisaldehyde Ethyl acrylate CHEMBRDG-BB 6596991

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.